The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Group B Streptococcus Infection Treatment Market Increase Between 2026 And 2030?

The group b streptococcus infection treatment market has demonstrated significant expansion in recent years. Its size is expected to increase from $1.26 billion in 2025 to $1.36 billion in 2026, at a compound annual growth rate (CAGR) of 8.3%. The growth observed in previous periods is attributable to several factors, including heightened awareness of neonatal infections, the proliferation of prenatal care programs, the extensive application of beta-lactam antibiotics, the development of hospital-based screening protocols, and the availability of microbiological testing services.

The market for group b streptococcus infection treatment is anticipated to experience robust expansion in the coming years. By 2030, this market is projected to reach $1.89 billion, advancing at a compound annual growth rate (CAGR) of 8.6%. This expansion during the forecast period is largely driven by factors such as the accelerated development of gbs vaccines, greater uptake of point-of-care diagnostic tools, a heightened emphasis on managing antimicrobial resistance, the broadening of molecular testing infrastructure, and a stronger focus on preventive maternal healthcare. Key trends anticipated for the forecast period encompass a surge in the adoption of rapid molecular diagnostic testing, an intensified focus on prenatal gbs screening programs, an increasing implementation of antibiotic stewardship protocols, the enlargement of therapeutic pipelines aimed at gbs prevention, and improved surveillance of maternal and neonatal outcomes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33144&type=smp

Which Strategic Drivers Are Supporting The Group B Streptococcus Infection Treatment Market Development?

The increasing healthcare expenditure is anticipated to propel the growth of the group B streptococcus infection treatment market moving forward. Healthcare expenditure is defined as the total financial resources allocated to medical services, preventive care, medications, infrastructure, and related health activities, all aimed at maintaining or improving population health. This expenditure is experiencing a rise due to the increasing prevalence of chronic and infectious diseases, which subsequently fuels sustained demand for long-term treatment, advanced therapies, and continuous medical care. A boost in healthcare expenditure strengthens group B Streptococcus infection treatment through heightened investment in prenatal screening, clinical infrastructure, and vaccine research. These combined efforts lead to improved early detection, prevention, and effective management of GBS infections in mothers and newborns. For instance, in April 2025, according to the Office for National Statistics, a UK-based government organization, overall healthcare spending increased by 6.5% from 2023 to 2024, indicating an acceleration compared with the 6.3% growth recorded in 2023. Therefore, the escalating healthcare expenditure is a key factor driving the growth of the group B streptococcus infection treatment market.

What Are The Major Segment Categories Within The Group B Streptococcus Infection Treatment Market?

The group b streptococcus infection treatment market covered in this report is segmented –

1) By Treatment Type: Antibiotic Therapy; Intravenous Immunoglobulin (IVIG); Experimental Therapies

2) By Drug Class: Beta-Lactam Antibiotic; Clindamycin And Alternatives; Pipeline Therapies

3) By Route of Administration: Oral Administration; Intravenous Administration; Topical Application

4) By Patient Type: Newborns; Pregnant Women; Immunocompromised Patients; Elderly Population

5) By End User: Hospitals; Clinics; Research Institutions; Home Care Settings

Subsegments:

1) By Antibiotic Therapy: Penicillin Based Antibiotics; Cephalosporin Antibiotics; Macrolide Antibiotics; Aminoglycoside Antibiotics

2) By Intravenous Immunoglobulin (IVIG): Standard Polyclonal Immunoglobulin; High Dose Immunoglobulin Therapy; Adjunctive Immunoglobulin Therapy

3) By Experimental Therapies: Vaccine Based Therapies; Monoclonal Antibody Therapies; Bacteriophage Therapies; Immunomodulatory Therapies

What Trends Are Affecting The Growth Of The Group B Streptococcus Infection Treatment Market?

Leading companies in the group B streptococcus infection treatment market are concentrating on developing novel products, such as polysaccharide conjugate vaccines, aimed at reducing asymptomatic bacterial carriage. These vaccines are immunizations where bacterial surface sugars are chemically linked to a carrier protein to enhance immune recognition and generate a strong, long-lasting protective response, especially beneficial for infants and young children. For example, in September 2023, Omniose, a US-based biotechnology company, announced a grant award of up to $3.0 million from the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health to support the development of a Group B Streptococcus (GBS) vaccine. The vaccine’s distinguishing feature is its objective to achieve high efficacy through a significantly simplified manufacturing method. Omniose’s platform employs synthetic biology and a one-step enzymatic process within a single re-engineered E. coli cell to produce GBS polysaccharide conjugate vaccines, thereby eliminating conventional chemical conjugation steps. This process preserves 100% of sialic acid residues on each capsular polysaccharide, a factor demonstrated to be critical for inducing strong functional antibody responses against specific GBS serotypes.

Which Companies Are Engaged In The Group B Streptococcus Infection Treatment Market Environment?

Major companies operating in the group b streptococcus infection treatment market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Biological E. Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Vaxcyte Inc., Bharat Biotech International Limited, Clover Biopharmaceuticals Ltd., Biovac Institute (Pty) Ltd., Inventprise Inc., BioNet Asia Co. Ltd., GeneOne Life Science Inc., Alopexx Enterprises LLC, Wellstat Vaccines LLC, MinervaX ApS, and ShanghAI Zerun Biotechnology Co. Ltd.

Access The Complete Group B Streptococcus Infection Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/group-b-streptococcus-infection-treatment-market-report

Which Region Holds The Largest Share In The Group B Streptococcus Infection Treatment Market?

North America was the largest region in the group B streptococcus infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the group b streptococcus infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Group B Streptococcus Infection Treatment Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model